New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
16:19 EDTSNY, REGNSanofi, Regeneron report positive proof-of-concept data for dupilumab
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
News For SNY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTREGNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use